ArticleAntioxidants (Basel, Switzerland)2020
Resveratrol Improves Heart Function by Moderating Inflammatory Processes in Patients with Systolic Heart Failure.
Article in Antioxidants (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Effects of resveratrol supplementation on renal function in adults: a systematic review and dose-response meta-analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities.International journal of molecular sciences · 2024Pooled it
- Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients.Molecular and cellular biochemistry · 2025Trial
- Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Trial
- Dietary Bioactive Compounds: Cellular Sensory Pathways, Microbial Partners, and Clinical Realities.Nutrients · 2026Review
- AMPK Signalling in Heart Failure: From Metabolic Sensor to Context-Dependent Therapeutic Target.Biomedicines · 2026Review
- Resveratrol and Redox Regulation in Cardiovascular Disease Across the Life Course: Mechanistic and Translational Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
- Beyond Conventional Treatment: Herbal Medicine and Nutraceuticals as Complementary Therapies for COPD and Asthma.The open respiratory medicine journal · 2026Review
- Proteomic Profiling of Cardiomyocytes Revealed Potential Radioprotective Effects of Different Resveratrol Pretreatment Regimens.International journal of molecular sciences · 2025Article
- From Plants to Protection: Cardiorenal Benefits in Non-Diabetic Chronic Kidney Disease and Heart Failure.Molecules (Basel, Switzerland) · 2025Review
- Antioxidants in Cardiovascular Health: Implications for Disease Modeling Using Cardiac Organoids.Antioxidants (Basel, Switzerland) · 2025Review
- Immunometabolism in heart failure.Nature reviews. Cardiology · 2025Review
- Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function.European journal of heart failure · 2025Review
- In vivo mechanisms of resveratrol liposomes in targeting the TLR4/NLRP3 pathway in lung cancer.Scientific reports · 2025Article
- Cellular and Molecular Bases for the Application of Polyphenols in the Prevention and Treatment of Cardiovascular Disease.Diseases (Basel, Switzerland) · 2025Review
- Associations between Dietary Phenolic Compounds and Biomarkers of Atrial Fibrillation Risk in Adults with Metabolic Syndrome: A Longitudinal Analysis.The Journal of nutrition · 2025Observational
- AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic hearts.Scientific reports · 2025Article
- Article
- Plant Polyphenols as Heart's Best Friends: From Health Properties, to Cellular Effects, to Molecular Mechanisms of Action.International journal of molecular sciences · 2025Review
- Recent advances in the interaction of ferroptosis and immune-mediated inflammation in cardiovascular disease: mechanisms and therapeutic potential.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
The effects of resveratrol (RES) in heart failure have already been evaluated in animal models; however, in human clinical trials, they have not been confirmed yet. The aim of this study was to assess the effects of resveratrol treatment in systolic heart failure patients (heart failure with reduced ejection fraction or HFrEF). In this human clinical trial, 60 outpatients with NYHA (New York Heart Association) class II-III HFrEF were enrolled and randomized into two groups: receiving either 100-mg resveratrol daily or placebo for three months. At the beginning and at the end of the study echocardiography, a six-minute walk test, spirometry, quality of life questionnaire, lab test and RNA profile analysis were performed. The systolic and diastolic left ventricular function, as well as the global longitudinal strain, were improved significantly in the resveratrol-treated group (RES). Exercise capacity, ventilation parameters and quality of life also improved significantly in the RES group. In parallel, the cardiac biomarker levels (N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and galectin-3) decreased in the treated group. The level of inflammatory cytokines decreased significantly after RES supplementation, as a consequence of the decreased expression level of leucocyte electron transport chain proteins. The main findings of our trial are that RES treatment added to the standard heart failure therapy improved heart function and the clinical condition by moderating the inflammatory processes in patients with HFrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.